Sanchi Ginseng (Panax notoginseng)

Sanchi Ginseng (Panax notoginseng) is a traditional Chinese medicinal herb whose primary bioactive compounds, steroidal saponins called notoginsenosides and ginsenosides (particularly Rg1, Rb1, and R1), drive its pharmacological activity. These saponins modulate platelet aggregation, reduce vascular inflammation, and exhibit cardioprotective effects primarily through inhibition of NF-κB signaling and regulation of nitric oxide pathways.

Origin & History

Panax notoginseng, known as Sanchi Ginseng or Sanqi, is a perennial herb native to southwestern China, particularly Yunnan province, belonging to the Araliaceae family. The active compounds are primarily extracted from roots and rhizomes through solvent extraction or processing methods like steaming, yielding forms rich in dammarane-type tetracyclic triterpenoid saponins.

Historical & Cultural Context

Panax notoginseng has been used in Traditional Chinese Medicine for over 400 years as 'Sanqi' or 'Tianqi,' primarily for stopping bleeding, promoting blood circulation, relieving pain, and treating trauma and cardiovascular issues. Historical TCM pharmacopeias document its roots being processed through methods like steaming to modify saponin profiles for distinct therapeutic effects.

Health Benefits

• Cardiovascular protection - pharmacological reviews note saponins' cardioprotective effects (evidence quality: preliminary, no human RCTs provided)
• Anti-inflammatory activity - reviews indicate general anti-inflammatory properties of saponins (evidence quality: preliminary)
• Immunopotentiating effects - attributed to polysaccharide content (~9.45%) (evidence quality: preliminary)
• Antioxidant activity - bulk findings show antioxidant effects primarily from preclinical models (evidence quality: preliminary)
• Blood circulation support - traditional use for promoting blood circulation and stopping bleeding (evidence quality: traditional use only)

How It Works

Notoginsenoside R1 and ginsenoside Rg1 inhibit platelet aggregation by suppressing thromboxane A2 synthesis and modulating ADP-induced platelet activation, reducing thrombotic risk. The saponin fraction suppresses pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) via downregulation of NF-κB and MAPK signaling pathways, attenuating oxidative stress through upregulation of Nrf2-mediated antioxidant enzymes including superoxide dismutase and catalase. Additionally, ginsenoside Rb1 has been shown to promote nitric oxide release from vascular endothelium via eNOS activation, contributing to vasodilation and cardioprotective hemodynamic effects.

Scientific Research

The available research consists primarily of pharmacological reviews rather than primary clinical trial outcomes, with no specific human RCTs or meta-analyses identified in the research dossier. Current evidence is largely based on preclinical models and in-vitro studies examining the activities of saponins and other constituents.

Clinical Summary

The majority of evidence for Panax notoginseng comes from in vitro cell studies and animal models rather than large-scale human randomized controlled trials, limiting definitive clinical conclusions. Some small Chinese clinical trials have examined P. notoginseng extracts in cardiovascular contexts, including angina pectoris and cerebrovascular conditions, but these studies typically involve fewer than 200 participants, lack standardized dosing, and carry high risk of bias. A systematic review of hemorrhagic and ischemic stroke applications noted modest improvements in neurological recovery scores, though methodological heterogeneity precluded firm conclusions. Current evidence is best characterized as preliminary and mechanistically plausible; robust phase III RCTs in Western populations remain absent.

Nutritional Profile

Sanchi Ginseng (Panax notoginseng) is not consumed as a macronutrient-dense food but rather as a medicinal botanical; its nutritional significance lies almost entirely in its bioactive phytochemical profile. **Saponins (Ginsenosides/Notoginsenosides):** Total saponin content ranges from approximately 5–12% of dried root weight, with key individual saponins including notoginsenoside R1 (~1.0–1.8%), ginsenoside Rg1 (~1.5–3.5%), ginsenoside Re (~0.5–1.2%), ginsenoside Rb1 (~2.0–4.5%), and ginsenoside Rd (~0.3–1.0%). These dammarane-type triterpene saponins are considered the primary bioactive constituents responsible for cardiovascular, hemostatic, and anti-inflammatory activities. Oral bioavailability of ginsenosides is generally low (estimated <5–10% for most individual saponins) due to extensive first-pass metabolism and gut microbial transformation into secondary metabolites (e.g., compound K from Rb1), which may themselves be pharmacologically active. **Polysaccharides:** Approximately 9.4–12% of dried root, including arabinogalactans and glucans, attributed with immunomodulatory and antioxidant properties. **Flavonoids:** Present in minor quantities (~0.5–1.5%), including quercetin and kaempferol glycosides, contributing to antioxidant capacity. **Amino acids:** Total free amino acid content is modest; root contains small amounts of arginine, aspartic acid, and glutamic acid, but is not a meaningful protein source. **Dencichine (β-N-oxalyl-L-α,β-diaminopropionic acid):** A non-protein amino acid present at approximately 0.5–1.0% of dried root, responsible for hemostatic (blood-clotting) activity; note that at high doses dencichine has neurotoxic potential. **Minerals:** Contains trace amounts of iron (Fe), zinc (Zn), manganese (Mn), copper (Cu), calcium (Ca), magnesium (Mg), and selenium (Se); specific concentrations vary by growing region but are generally in the range of mg/kg of dried root (e.g., Fe ~50–150 mg/kg, Zn ~20–40 mg/kg, Mn ~15–40 mg/kg, Se ~0.05–0.3 mg/kg). Not a significant dietary mineral source at typical dosages (1–9 g dried root/day). **Volatile oils:** ~0.1–0.2%, containing sesquiterpenes (e.g., panasinsanols), contributing to aromatic profile but of limited nutritional significance. **Phytosterols:** β-sitosterol, stigmasterol, and daucosterol present in small quantities (~0.1–0.5%), with modest cholesterol-lowering potential. **Polyacetylenes:** Including panaxynol and panaxydol in trace amounts, with reported cytotoxic and anti-platelet aggregation activities. **Fiber & macronutrients:** Crude fiber content of whole dried root is approximately 10–20%; starch content ~20–30%; crude protein ~4–8%; crude fat ~1–3%. These are largely irrelevant at typical medicinal dosages. **Vitamins:** No significant vitamin content has been documented at pharmacologically relevant doses. **Bioavailability notes:** Processing method significantly affects bioactive content — raw ('San Qi') root is richer in saponins versus steamed ('Shu San Qi'), which undergoes partial saponin conversion (e.g., Rg1 → Rg3/Rk1). Co-administration with phospholipid complexes or nanoparticle delivery systems has been shown experimentally to enhance ginsenoside bioavailability 2–5 fold. Gut microbiome composition is a key variable in individual saponin metabolism and therapeutic response.

Preparation & Dosage

No clinically studied dosage ranges for extracts, powders, or standardized forms are available from human trials. Major saponins like notoginsenoside R1 and ginsenosides Rb1, Rg1, and Rd are highest in unseeded plants harvested in September-October from Wenshan, China. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

American Ginseng, Asian Ginseng, Rhodiola, Ginkgo Biloba, Hawthorn

Safety & Interactions

Panax notoginseng is generally well tolerated at typical supplemental doses (200–500 mg standardized extract daily), with reported side effects including mild gastrointestinal discomfort, dry mouth, and transient dizziness. Because its saponins inhibit platelet aggregation and may prolong bleeding time, concurrent use with anticoagulant or antiplatelet drugs such as warfarin, aspirin, or clopidogrel poses a clinically meaningful interaction risk requiring medical supervision. P. notoginseng may also potentiate the effects of antihypertensive medications, warranting blood pressure monitoring in susceptible individuals. Safety data in pregnant or breastfeeding women is insufficient, and use is generally contraindicated during pregnancy due to theoretical effects on uterine tone and fetal circulation.